Zucker Fatty Rat (ZFR) Model Preclinical Services
At Ace Therapeutics, we provide specialized preclinical research services utilizing the ZFR model to support drug development for obesity and metabolic disorders. Our expertise in study design, execution, and data analysis ensures robust and reliable results for our clients.
The Zucker Fatty Rat (ZFR) is a well-established genetic model for studying obesity and its metabolic complications. Characterized by a spontaneous mutation in the leptin receptor gene (fa/fa), ZFRs develop hyperphagia, early-onset obesity, insulin resistance, dyslipidemia, and progressive glucose intolerance—phenotypes that closely mirror human metabolic syndrome. This model is particularly valuable for investigating the pathophysiology of obesity, evaluating therapeutic interventions, and identifying biomarkers associated with disease progression.
Fig.1. Zucker fatty fa/fa rats as an established genetic model of obesity. (Hankir, M. K. et al. 2021)
At Ace Therapeutics, we leverage the ZFR model to deliver robust preclinical insights for obesity-related drug discovery and development. Our services focus on generating actionable data to support target validation, efficacy testing, and mechanistic studies, enabling clients to advance promising candidates with confidence.
Conduct comprehensive toxicology assessments, including histopathological evaluations of liver, adipose tissue, and cardiovascular systems.
Explore synergistic effects of multi-target approaches to address obesity's multifactorial nature.
The ZFR model supports a broad spectrum of obesity-related research applications:
Choosing the right preclinical research partner is crucial for obtaining high-quality data that informs drug development decisions. Ace Therapeutics offers the following advantages:
What makes the Zucker Fatty Rat (ZFR) model suitable for obesity research?
The ZFR model is a genetically modified rat strain that develops spontaneous obesity due to a mutation in the leptin receptor (fa/fa) gene. This model exhibits key features of human obesity, including hyperphagia, insulin resistance, and dyslipidemia, making it a valuable tool for preclinical obesity research.
How are studies designed using the ZFR model?
Each study is customized based on the research objectives. We define experimental endpoints such as body weight changes, glucose tolerance, insulin sensitivity, lipid profile, and inflammatory markers to assess therapeutic effects. Study duration and dosing regimens are optimized based on specific project needs.
What types of analysis can be performed using the ZFR model?
We offer a comprehensive range of analyses, including biochemical assays (glucose, insulin, lipid panels), histological assessments (adipose tissue, liver, pancreas), gene expression profiling, and metabolic phenotyping.
Can Ace Therapeutics provide customized study designs?
Yes. We tailor our preclinical studies to meet client-specific objectives, offering flexibility in dosing strategies, biomarker selection, and endpoint analysis to optimize study outcomes.
How do you ensure data quality and reproducibility?
We employ rigorous study protocols, standardized methodologies, and robust statistical analyses to ensure high-quality, reproducible results. Our experienced team carefully monitors all study phases to maintain data integrity.
Reference
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics is a preclinical research leader specializing in obesity and metabolic disorders, offering validated models and advanced analytics to accelerate anti-obesity drug development. With a decade of expertise, we deliver end-to-end solutions, empowering biopharma innovators to transform therapies from concept to preclinical success.